CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 47 enrolled
Drug / intervention
GnRH agonist +2 moredrug
Likely dose
GnRH agonist 3.75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01712230
NCT01712230N/ACompleted
CompareCT.gov

Bioenergetic and Metabolic Consequences of the Loss of Ovarian Function in Women

University of Colorado, Denver·interventional·Posted Oct 23, 2012·Updated Nov 22, 2019

In Brief

A clinical study evaluating GnRH agonist, Supervised cardiovascular exercise, and 1 other intervention for Obesity. Completed, enrolled 47 participants across 1 site.

Detailed Summary

This study is designed to determine whether a reduction in hormones (such as occurs during menopause) causes a decrease in calories burned during physical activity. This study will also determine whether a reduction in hormones decreases calories burned while sleeping, resting, and eating and whether an exercise intervention can prevent this.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 23, 2012
Enrollment StartOct 1, 2012
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 13.7 years ago

Interventions

GnRH agonistdrug

Drug: leuprolide acetate Other Names: Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months

Supervised cardiovascular exercisebehavioral

Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months

Placebodrug

Placebo